Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2021, with a specific reporting date of July 13, 2021. The document serves as a transaction notification regarding dealings in the company's ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Volume | Transaction Type |
|---|---|---|---|---|
| July 9, 2021 | Ordinary Shares (25p each) | £14.3320 | 29 | Acquisition (Dividend Re-investment) |
| July 9, 2021 | Ordinary Shares (25p each) | £14.3320 | 25 | Acquisition (Dividend Re-investment) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of shares by executives following the re-investment of dividends paid on July 8, 2021, within Individual Savings Accounts (ISAs).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Transaction Nature: The reported share purchases were automatic acquisitions resulting from dividend re-investment plans, not discretionary open-market purchases.
- Executives Involved: Mr. D. Redfern (Chief Strategy Officer) and Ms. V. Whyte (Company Secretary).
- Market Price: The shares were acquired at £14.3320 on the London Stock Exchange.
- Volume: The total volume reported in this specific filing is 54 shares (29 + 25), representing a negligible percentage of total outstanding shares.